The PREDICT Registry:
(PREDICT Trial)

Recruiting in Palo Alto (17 mi)

+66 other locations

Overseen byTroy Bremer, PhD

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: PreludeDx

No Placebo Group

Trial Summary

What is the purpose of this trial?

This is a prospective, non-interventional (observational) cohort study conducted within the medical network of the participating investigators and institutions. Patients meeting the eligibility criteria (see below) will be eligible for participation and the investigators will obtain written informed consent. A central Institutional Review Board (IRB), WCG IRB, will approve the protocol and each participating institution.

Eligibility Criteria

Inclusion Criteria

Patient must have histologically confirmed ductal carcinoma in situ (DCIS) in a single breast (presence of lobular carcinoma in situ (LCIS) or other benign breast disease in addition to DCIS is acceptable)

Patient must have the DCISionRT™ Test ordered during routine patient care

Patient must be planning to undergo breast conserving surgery

See 4 more

Treatment Details

Interventions

DCISionRT Test (Gene Expression Profiling)

Participant Groups

1Treatment groups

Experimental Treatment

Group I: DCISExperimental Treatment2 Interventions

Patients must have histologically confirmed ductal carcinoma in situ (DCIS) in a single breast without evidence of invasive cancer (presence of lobular carcinoma in situ (LCIS) or other benign breast disease in addition to DCIS is acceptable)